TITLE

Human tyrosyl-DNA phosphodiesterase 1: new activities and development of enzyme inhibitors as anticancer drugs

AUTHOR(S)
Lavrik, O.
PUB. DATE
December 2015
SOURCE
Biopolymers & Cell;2015 Suppl. 5, p13
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tyrosyl-DNA phosphodiesterase 1 (TDP1) is responsible to process topoisomerase 1 (TOP1) - DNA adducts as well as to hydrolyze a variety of other DNA 3'-substituents. We have shown recently that TDP1 can initiate repair of apurinic/apyrimidinic (AP) sites located in the internal positions of DNA generating breaks with the 3'- and 5'-phosphate termini [1-3]. This activity was not observed for TDP1 SCAN mutant responsible for neurodegeneration. Polynucleotide kinase phosphatase, Polß and DNA ligase coordinated with XRCC1 are completing repair of the AP sites. The AP site cleaving activity of TDP1 is shown to be stimulated by the key modulator of base excision repair (BER) - poly(ADP-ribose)polymerase 1 (PARP1). The data suggest a role of TDP1 in the new APE1-independent BER pathway in mammals. This activity can contribute to repair of AP sites particularly in ssDNA structures or in the context of cluster-type lesions. The specific real-time fluorescent detection of the AP-site cleaving activity of TDP1 was developed, which is not sensitive to AP site cleavage by APE1 and useful to evaluate a biological significance of new TDP1 function to initiate cleavage of AP sites. TDP1 is a promising target for antitumor therapy based on TOP1 poison-mediated DNA damage. The row of novel benzopentathiepins and other compounds were synthesized and tested as TDP1 inhibitors using an original oligonucleotide-based fluorescence assay [4]. The benzopentathiepines showed IC50 values in the range of 0.2-6.0 µM. The specificity of these inhibitors was investigated by using other target DNA repair proteins such as PARP1, PARP2, AP-endonuclease 1 and DNA polymerase beta. The study of cytotoxicity of these compounds revealed that their action leads to the apoptotic cell death of cancer cells. Therefore the new class of very effective inhibitors of TDP1 was elaborated, which are very prominent to improve cancer therapy based on TOP1 poison-mediated DNA damage.
ACCESSION #
111992336

 

Related Articles

  • Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells. Mayur, Y. C.; Peters, G. J.; Prasad, V. V. S. Rajendra; Lemos, C.; Sathish, N. K. // Current Cancer Drug Targets;May2009, Vol. 9 Issue 3, p298 

    Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some have undergone clinical trials, but currently none are in clinical use. Unfortunately, most of...

  • Fresh from the pipeline: Gefitinib. Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p515 

    Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor. Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced...

  • In this issue.  // Nature Reviews Drug Discovery;Nov2010, Vol. 9 Issue 11, p821 

    The article discusses various reports published within the issue, including one by Brinkmann and colleagues on the case history of fingolimod, one by Cohen on cyclical development strategy, and one by Doroshow and colleagues on their evaluation of anticancer agents at the U.S. National Cancer...

  • Anticancer chemotherapy. Davey, Peter; Tudhope, G.R. // British Medical Journal (Clinical Research Edition);7/9/1983, Vol. 287 Issue 6385, p107 

    Features several of the latest cytotoxic drugs and its applications in Great Britain. Current drugs and their analogues; Developments with antimetabolites; Enumerations on latest cytotoxic drugs.

  • Current Targets for Anticancer Drug Discovery. N-H. Nam; K. Parang // Current Drug Targets;Feb2003, Vol. 4 Issue 2, p159 

    The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biology have led to the...

  • Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase. Nivens, Michael C.; Felder, Takita; Galloway, Amanda H.; Pena, Maria Marjorette O.; Pouliot, Jeffery J.; Spencer, H. Trent // Cancer Chemotherapy & Pharmacology;Feb2004, Vol. 53 Issue 2, p107 

    Purpose. Gene transfer of cDNA sequences that confer drug resistance can be used (1) to protect hematopoietic cells against the toxic effects of chemotherapy, (2) for in vivo enrichment of genetically engineered cells and (3) to protect cytotoxic T lymphocytes in drug-resistant immunotherapy...

  • Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex. Jana Ka?párková; Fiona S. Mackay; Viktor Brabec; Peter J. Sadler // Journal of Biological Inorganic Chemistry;Sep2003, Vol. 8 Issue 7, p741 

    Platinum(II) diam(m)ine complexes such as cisplatin are effective anticancer drugs but have accompanying side effects. We are exploring the design of platinum complexes with low toxicity that could be photoactivated selectively at the target site. We show here that the Pt(IV) azide complex cis,...

  • Targeting cancer stem cells. Feliciano, Pamela // Nature Genetics;Jul2012, Vol. 44 Issue 7, p739 

    The article focuses on the efforts to develop drugs that selectively target cancer stem cells which bear cancers.

  • Wondering What You Missed in BioWorld Insight?  // BioWorld Today;5/30/2012, p7 

    The article presents an overview of the reports in "BioWorld Insight" journal, including a report which explored the technologies that are making undruggable targets accessible to therapeutic intervention and the withdrawal of lung cancer drug Iressa (gefitinib) in the U.S.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics